Future Therapies of Wet Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population, and the prevalence of the disease increases exponentially with every decade after the age of 50 years. While VEGF inhibitors are promising drugs for treating patients with ocular neovascularization, t...
Saved in:
Main Authors: | Makoto Ishikawa, Daisuke Jin, Yu Sawada, Sanae Abe, Takeshi Yoshitomi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Journal of Ophthalmology |
Online Access: | http://dx.doi.org/10.1155/2015/138070 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Vitrectomy for full-thickness macular hole developed during aflibercept treatment for wet age-related macular degeneration
by: Agnieszka Nowosielska
Published: (2024-12-01) -
Saffron therapy for the ongoing treatment of age-related macular degeneration
by: Peter J McCluskey, et al.
Published: (2024-07-01) -
Management of Wet Age-Related Macular Degeneration in Spain: Challenges for Treat and Extend Implementation in Routine Clinical Practice
by: A. García-Layana, et al.
Published: (2019-01-01) -
Mechanism of Inflammation in Age-Related Macular Degeneration
by: Francesco Parmeggiani, et al.
Published: (2012-01-01) -
Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study
by: Ermete Giancipoli, et al.
Published: (2018-01-01)